electroCore (ECOR) investor relations material

Business overview and strategy

• Focuses on bioelectronic medicine and wellness, targeting multiple indications including headache, fibromyalgia, sleep, stress, and focus.

• Offers a range of products and business models for diverse end users, including Rx and general wellness devices.

• Pursues growth through expanding indications, consumer wellness, and human performance markets.

• Strategic pivots include the NeuroMetrix acquisition, strengthening VA hospital channels, and developing the wellness business.

Product portfolio and innovation

• gammaCore is FDA-cleared for primary headache prevention and treatment, with no drug interactions or significant side effects.

• Quell is the first FDA-authorized non-invasive device for fibromyalgia symptom relief, with $1.5M revenue since acquisition.

• Truvaga and TAC-STIM are general wellness products targeting stress, sleep, focus, and human performance, not FDA-evaluated.

• Pipeline includes potential label extensions for PTSD, mTBI, and chemotherapy-induced neuropathy.

Market opportunity and channels

• Addresses large markets: $20B annual out-of-pocket chronic pain spend, 39M US adults with primary headache, 6% with fibromyalgia.

• Active revenue channels include VA hospitals, commercial clinics, eCommerce, and international markets.

• Significant opportunity to expand fibromyalgia offering in VA channel, with 40% prevalence.